Lung cancer is a leading cause of cancer-related death worldwide, and treatment options are limited for patients with advanced disease. However, a recent study published in the journal Nature has shown promising results for a new approach to treating lung cancer using personalized medicine. The researchers analyzed the genomes of more than 2,000 patients with non-small cell lung cancer and identified several genetic mutations that were associated with a better response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer. The researchers also developed a personalized treatment algorithm that took into account the genetic mutations of each patient’s tumor. They found that patients who received personalized treatment based on their tumor’s genetic profile had a better response to immunotherapy than those who received standard treatment. The lead author of the study, Dr. Trever Bivona, said that the results were “very promising” and showed that personalized ...
CPhI is an established pharmaceutical event with over 30 years' experience of bringing together the movers and shakers in pharma. Uniting niche and top buyers and sellers together under one roof in nine event locations around the world, CPhI hosts quality conferences, free seminars, Awards and even pharma community charity expeditions.
The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The fair takes place once a year in Dusseldorf and is open to trade visitors only. Rising life expectancy, medical progress and the growing awareness of the people for their health are helping to increase the demand for modern treatment methods. This is where the Medica grabs and provides the medical device industry a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The exhibition is divided into the areas of electromedicine and medical technology, information and communication technology, physiotherapy and orthopedic technology, disposables, commodities and consumer goods, laboratory equipment and diagnostic products. In addition to the trade fair the Medica conferences and forums belong to the firm offer of this fair, which are complemented by numerous activities and interesting special shows. The Medica is held in conjunction with the world's largest supplier fair for medicine, Compamed. Thus, the entire process chain of medical products and technologies are presented to the visitors and necessitates a visit to the two exhibitions for each industry expert.
Vitamins are trace organic substances that humans and animals must obtain from food to maintain normal physiological functions. They play an important role in human growth, metabolism, and development.
Rheumatoid arthritis (RA) is an autoimmune disease with complex pathogenesis and an extremely high morbidity rate, which seriously affects the quality of the life of patients and brings economic burden to society. Thus, effective treatments of RA has become a global concern of the pharmaceutical industry.
Diabetes is one of the most common chronic diseases and is mainly classified into type 1 diabetes, type 2 diabetes, gestational diabetes and others. Worldwide, 90% of diabetic patients suffer from type 2 diabetes, which greatly promotes the development of the diabetes drug market.
Research by the World Health Organization has shown that“Physically, it is much more difficult to stop the production of millions of sperm per day for men than to prevent women from releasing an egg every month.” In the contraceptive drugs market, contraceptive drugs for women account for 90%, and is gradually becoming just as accepted in China as it is in most other parts of the world.
GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for use in adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen. The authorisation is based on results from the open-label GARNET study, which included women with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed on or after a platinum-based chemotherapy regimen. Jemperli treatment led to an objective response rate of 44.8% and a disease control rate of 57.1%, while a median duration of response (DoR) had not been reached in these patients. However, the probability of maintaining a response at six months and 12 months was 97.9% and 90.9% respectively, according to ...
The European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have validated Vertex’ applications to expand the scope of its cystic fibrosis (CF) treatment Kaftrio (ivacaftor/tezacaftor/elexacaftor). The drugmaker is seeking approval for the drug’s use in combination with ivacaftor in patients ages six years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, this will extend the indication for the triple combination therapy to children ages six through 11 years old in EU countries, Great Britain and Northern Ireland. In children with CF, symptoms and organ damage including lung disease manifest very early in life. “We are committed to working diligently with global regulators to expand the indication for our medicine such that younger people living with CF will also be able to access the triple combination therapy,” said Nia Tatsis, executive VP, chief regulatory ...
New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity. The STEP 1 trial demonstrated benefits for people with obesity treated with semaglutide 2.4mg ‘beyond weight loss’, Novo said in a statement. Over a 68-week period, treatment with once-weekly semaglutide 2.4mg was associated with greater improvements for all weight- and health-related quality of life scores in people with obesity or overweight in comparison to placebo. This included improved wellbeing, with 43.8% of patients treated with Novo’s drug achieving a clinically meaningful improvement in total weight-related quality of life score at week 68. On top of that, 51.2% of participants treated with semaglutide 2.4mg in the trial had an increased weight-related physical function score, reflecting improvements in the ability to perform daily activities. In addition, patients treated with semaglutide 2.4mg ‘simultaneously’ experienced significant weight loss of ...
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.